Preview

Нефрология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК И АРИТМИИ: ИТОГИ КОНФЕРЕНЦИИ KDIGO ПО СПОРНЫМ ВОПРОСАМ

https://doi.org/10.24884/1561-6274-2019-23-2-18-40

Полный текст:

Аннотация

Пациенты, страдающие хронической болезнью почек (ХБП), имеют предрасположенность к развитию таких нарушений ритма, как фибрилляция предсердий (ФП)/ трепетание предсердий, наджелудочковая тахикардия и внезапная сердечная смерть (ВСС). Несмотря на то, что существуют разнообразные терапевтические возможности, включая лекарственное лечение, использование приборов и применение других мероприятий, их использование при ХБП остается затруднительным и ограниченным. Пациентов с ХБП, в том числе с терминальной почечной недостаточностью, обычно не включают в рандомизированные исследования по лечебным стратегиям при аритмиях, хотя эта ситуация в настоящее время претерпевает изменения. Консенсус сердечно-сосудистого общества кардиологов не так давно выявил этот пробел в лечении пациентов с ХБП и нарушениями сердечного ритма. С целью установления основных аспектов, относящихся к наилучшему предотвращению, оптимальному ведению таких больных и лечению аритмий и их осложнений, группа Kidney Disease: Improving Global Outcomes (KDIGO) провела международную мультидисциплинарную конференцию «ХБП и аритмии» в Берлине, Германия, в октябре 2016 г.

Для доступа к материалу требуется подписка или приобретенный доступ. Чтобы подтвердить подписку и доступ, либо приобрести материал, пожалуйста войдите в систему.

Об авторах

Минту П. Турахия
Университетская медицинская школа Стэндфорда, г. Пало Альто
Соединённые Штаты Америки


Петер Дж. Бланкештин
Университетского медицинского центра, г. Утрехт, Нидерланды
Нидерланды
отделение нефрологии


Хуан-Хесус Карреро
Каролинский Институт, г. Стокгольм
Швеция
отделение медицинской эпидемиологии и биостатистики


Катерин М. Клазе
Университет Макмастера
Канада
отделение Медицины и отделение научных методов исследования в медицине


Райат Део
Школа медицины Перельмана Университета Пенсильвании
Соединённые Штаты Америки

секция электрофизиологии, отделение сердечно-сосудистой медицины



Чарльз А. Герцог
отдел кардиологии, отделение медицины Медицинского центра округа Хеннипин и Университета Миннесоты, Миннеаполис, Миннесота и Группа по изучению хронических заболеваний, Научный медицинский фонд Миннеаполиса
Соединённые Штаты Америки


Скотт Е. Каснер
больница Университета Пенсильвании, Филадельфия
Соединённые Штаты Америки
отделение неврологии


Род С. Пассам
Медицинская школа Северо-Западного университета имени Файнберга и Седечной-сосудистый институт Блума, г. Чикаго
Соединённые Штаты Америки


Роберто Пекуа-Фийо
Школа медицины, Папский католический университет Параны, Куритиба
Бразилия


Холгер Райнеке
Университетская клиника Мюнстера, Мюнстер
Германия
отделение кардиологии и ангиологии


Гаутам Р. Шрофф
Медицинский центр округа Хеннипин, Миннеаполис
Соединённые Штаты Америки
отделение кардиологии


Войцех Зареба
Программа по изучению сердца, Университет Медицинского центра Рочестера, Рочестер
Соединённые Штаты Америки


Майкл Чеунг
Офис Kdigo, Брюссель
Бельгия


Дэвид К. Вилер
Центр нефрологии, Университетский колледж Лондона, Лондон
Великобритания


Кристоф Ваннер
отдел нефрологии, отделение медицины, Университетская клиника Вюрцбурга, г. Вюрцбург
Германия


Вольфганг К. Винкельмайер
Институт здоровья почек Зельцмана, секция нефрологии, отделение медицины, колледж медицины Бэйлора, Хьюстон
Соединённые Штаты Америки


Список литературы

1. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006;70:2021–2030. Doi: https://Doi.org/10.1038/ sj.ki.5001934

2. Konstantinidis I, Nadkarni GN, Yacoub R et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 2016;176: 121–124. Doi: https://Doi.org/10.1001/jamainternmed.2015.6102

3. Boriani G, Savelieva I, Dan GA et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015;17: 1169–1196. Doi: https://Doi. org/10.1093/europace/euv202

4. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17: 1467–1507. Doi: https://Doi. org/10.1093/europace/euv309

5. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962. Doi: https://Doi. org/10.1093/ejcts/ezw313

6. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381. Doi: https://Doi. org/10.1093/eurheartj/ehw106

7. Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the. European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–2867. Doi: https://Doi.org/10.1714/2174.23496

8. Chugh SS, Havmoeller R, Narayanan K et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129: 837–847. Doi: https://Doi. org/10.1161/CIRCULATIONAHA.113.005119

9. Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158–169. Doi: https://Doi.org/10.1016/S0140-6736(13)60439-0

10. Soliman EZ, Prineas RJ, Go AS, Xie D et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102–1107. Doi: https://Doi.org/10.1016/j.ahj.2010.03.027

11. Ananthapanyasut W, Napan S, Rudolph EH et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5: 173–181. Doi: https://Doi.org/10.2215/CJN.03170509

12. McManus DD, Corteville DC, Shlipak MG et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol 2009;104:1551–1555. Doi: https://Doi.org/10.1016/j.amjcard.2009.07.026

13. Zimmerman D, Sood MM, Rigatto C et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27: 3816–3822. Doi: https://Doi.org/10.1093/ndt/gfs416

14. Wetmore JB, Mahnken JD, Rigler SK et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/ Medicaid-eligible dialysis patients. Kidney Int 2012; 81:469–476. Doi: https://Doi.org/10.1038/ki.2011.416

15. Genovesi S, Pogliani D, Faini A et al. Prevalence of atrial fibrillation and associated factors in a population of longterm hemodialysis patients. Am J Kidney Dis 2005;46:897–902. Doi: https:// Doi.org/10.1053/j.ajkd.2005.07.044

16. Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77: 1098–1106. Doi: https:// Doi.org/10.1038/ki.2009.477

17. Roy-Chaudhury P, Williamson DE, Tumlin JA, Charytan DM, Prakash K, Kher VK. Arrhythmic risk in patients with type II diabetes on hemodialysis: preliminary results from the Monitoring in Dialysis (MiD) Clinical Study. Abstract THPO805. J Am Soc Nephrol 2015;26:275A

18. Konigsbrugge O, Posch F, Antlanger M et al. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDI-alysis (VIVALDI). PLoS One 2017;12:e0169400. Doi: https://Doi. org/10.1371/journal.pone.0169400

19. Alonso A, Lopez FL, Matsushita K et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:2946–2953. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.111.020982

20. Sandhu RK, Kurth T, Conen D et al. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol 2012; 109:538–542. Doi: https://Doi.org/10.1016/j.amjcard.2011.10.006

21. Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158:629– 636. Doi: https://Doi.org/10.1016/j.ahj.2009.06.031

22. Horio T, Iwashima Y, Kamide K et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010;28:1738–1744. Doi: https://Doi.org/10.1097/HJH.0b013e32833a7dfe

23. Shang W, Li L, Huang S et al. Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. PLoS One 2016;11:e0155581. Doi: https://Doi.org/10.1371/journal.pone.0155581

24. Alonso A, Krijthe BP, Aspelund T et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013;2:e000102. Doi: https://Doi.org/10.1161/JAHA.112.000102

25. Deo R, Katz R, Kestenbaum B et al. Impaired kidney function and atrial fibrillation in elderly subjects. J Card Fail 2010;16:55–60. Doi: https://Doi.org/10.1016/j.cardfail.2009.07.002

26. Liao JN, Chao TF, Liu CJ et al. Incidence and risk factors for newonset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 2015;87:1209–1215. Doi: https://Doi.org/10.1038/ki.2014.393

27. Goldstein BA, Arce CM, Hlatky MA et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012;126:2293–2301. Doi: https:// Doi.org/10.1161/CIRCULATIONAHA.112.099606

28. Winkelmayer WC, Patrick AR, Liu J et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011;22:349–357. Doi: https://Doi.org/10.1681/ ASN.2010050459

29. Providência R, Marijon E, Boveda S et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 2014;114:646–653. Doi: https://Doi.org/10.1016/j. amjcard.2014.05.048

30. Piccini JP, Stevens SR, Chang Y et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127:224– 232. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.112.107128

31. Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625–635. Doi: https://Doi.org/10.1056/NEJMoa1105594

32. Go AS, Fang MC, Udaltsova N et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363–1369. Doi: https://Doi. org/10.1161/CIRCULATIONAHA.108.816082

33. Wetmore JB, Ellerbeck EF, Mahnken JD et al. Atrial fibrillation and risk of stroke in dialysis patients. Ann Epidemiol 2013;23:112–118. Doi: https://Doi.org/10.1016/j.annepidem.2012.12.011

34. Conen D, Chae CU, Glynn RJ et al. Risk of death and cardiovascular events in initially healthy women with newonset atrial fibrillation. JAMA 2011;305:2080–2087. Doi: https://Doi. org/10.1001/jama.2011.659

35. Shih CJ, Ou SM, Chao PW et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 2016;133:265–272. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.115.018294

36. Lenihan CR, Montez-Rath ME, Scandling JD et al. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transplant 2013;13:1566–1575. Doi: https://Doi.org/10.1111/ajt.12197

37. Findlay MD, Thomson PC, MacIsaac R et al. Risk factors and outcome of stroke in renal transplant recipients. Clin Transplant 2016; 30: 918–924. Doi: 10.1111/ctr.12765

38. Bansal N, Xie D, Tao K et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol 2016; 11: 1189–1196. Doi: 10.2215/CJN.10921015

39. Bansal N, Fan D, Hsu CY et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013; 127: 569–574. Doi: 10.1161/CIRCULATIONAHA.112.123992

40. O’Neal WT, Tanner RM, Efird JT et al. Atrial fibrillation and incident end-stage renal disease: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Int J Cardiol 2015; 185: 219–223. Doi: 10.1016/j.ijcard.2015.03.104

41. Bansal N, Fan D, Hsu CY et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc 2014; 3: e001303. Doi: 10.1161/JAHA.114.001303

42. Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc 2012; 1: e002097. Doi: 10.1161/JAHA.112.002097

43. Chan PH, Huang D, Yip PS et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace 2016; 18: 665–671. Doi: 10.1093/ europace/euv289

44. Chao TF, Liu CJ, Wang KL et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014; 11: 1752–1759. Doi: 10.1016/j.hrthm.2014.06.021

45. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: 297–306. Doi: 10.1093/eurheartj/ehu139

46. Roldan V, Marin F, Manzano-Fernandez S et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013; 109: 956–960. Doi: 10.1160/TH13-01-005

47. Singer DE, Chang Y, Borowsky LH et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2: e000250. Doi: 10.1161/JAHA.113.000250

48. Kerr KF, Wang Z, Janes H et al. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology 2014; 25: 114–121. Doi: 10.1097/EDE.0000000000000018

49. January CT, Wann LS, Alpert JS et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: 2246–2276. Doi: 10.1016/j.jacc.2015.09.018

50. Bonde AN, Lip GY, Kamper AL et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014; 64: 2471–2482. Doi: 10.1016/j.jacc.2014.09.051

51. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 1S–70S, e1S–e801S. Doi: 10.1378/ chest.1412S3

52. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47: 895–900. Doi: 10.1161/STROKEAHA.115.012004

53. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151. Doi: 10.1056/NEJMoa0905561

54. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891. Doi: 10.1056/NEJMoa1009638

55. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992. Doi: 10.1056/NEJMoa1107039

56. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093–2104. Doi: 10.1056/NEJMoa1310907

57. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2599–2604. Doi: 10.2215/ CJN.02400311

58. Hijazi Z, Hohnloser SH, Oldgren J et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129:961–970. Doi: 10.1161/CIRCULATIONAHA.113.003628

59. Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394. Doi: 10.1093/ eurheartj/ehr342

60. Hohnloser SH, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821–2830. Doi: 10.1093/eurheartj/ehs274

61. Eikelboom JW, Connolly SJ, Gao P et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012; 21:429–435. Doi: 10.1016/j.jstrokecerebrovasdis.2012.05.007

62. Bohula EA, Giugliano RP, Ruff CT et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134:24–36. Doi: 10.1161/CIRCULATIONAHA.116.022361

63. Qamar A, Bhatt DL. Anticoagulation therapy: balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 2015; 11:200–202. Doi: 10.1038/nrneph.2015.14

64. Lau YC, Proietti M, Guiducci E et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol 2016; 68:1452–1464. Doi: 10.1016/j.jacc.2016.06.057

65. Tan J, Liu S, Segal JB et al. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol 2016; 17:157. Doi: 10.1186/s12882-016-0368-6

66. Hayashi M, Takamatsu I, Kanno Y et al. A case-control study of calciphylaxis in Japanese endstage renal disease patients. Nephrol Dial Transplant 2012; 27:1580–1584. Doi: 10.1093/ndt/ gfr658

67. Carrero JJ, Evans M, Szummer K et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014; 311: 919–928. Doi: 10.1001/jama.2014.1334

68. Szummer K, Gasparini A, Eliasson S et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017; 6:e004925. Doi: 10.1161/JAHA.116.004925

69. Yang F, Hellyer JA, Than C et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017; 103:818–826. Doi: 10.1136/ heartjnl-2016-309266

70. Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? Jama 2014; 311:913–915. Doi: 10.1001/jamasurg.2014.926

71. Brodsky SV, Nadasdy T, Rovin BH et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80:181–189. Doi: 10.1038/ki.2011.44

72. Holden RM, Booth SL. Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 2007; 3:522–523. Doi: 10.1038/ncpneph0601

73. Kooiman J, van der Hulle T, Maas H et al. Pharmacokinetics and pharmacodynamics of dabigatran 75 mg b.i.d. in patients with severe chronic kidney disease. J Am Coll Cardiol 2016; 67:2442–2444. Doi: 10.1016/j.jacc.2016.03.516

74. Dias C, Moore KT, Murphy J et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016; 43:229–236. Doi: 10.1159/000445328

75. De Vriese AS, Caluwe R, Bailleul E et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 91–98. Doi: 10.1053/j.ajkd.2015.01.022

76. Wang X, Tirucherai G, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with endstage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628–636. Doi: 10.1002/jcph.628

77. Mavrakanas TA, Samer CF, Nessim SJ et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28: 2241–2248. Doi: 10.1681/ASN.2016090980

78. Matzke GR, Aronoff GR, Atkinson AJ et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122–1137. Doi: 10.1038/ ki.2011.322

79. Manzano-Fernández S, Andreu-Cayuelas JM, Marı´n F et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed) 2015; 68: 497–504. Doi: 10.1016/j. rec.2014.06.026

80. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3 (Suppl): 1–150.

81. Chan KE, Edelman ER, Wenger JB et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131: 972–979. Doi: 10.1161/CIRCULATIONAHA.114.014113.

82. Winkelmayer WC, Herzog CA, Montez-Rath ME et al. Use of novel oral anticoagulants in patients with end-stage renal disease. Hemodial Int 2015; 19: 150–153. Doi: 10.1111/hdi.12251.

83. Shroff GR. Renal function in patients with atrial fibrillation receiving anticoagulants: the canaries in the coal mine. JAMA Cardiol 2016; 1: 375–376. Doi: 10.1001/jamacardio.2016.1258.

84. Yao X, Shah ND, Sangaralingham LR et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69: 2779–2790. Doi: 10.1016/j.jacc.2017.03.600

85. Kirchhof P, Breithardt G, Bax J et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016; 18: 37–50. Doi: 10.1093/ europace/euv304.

86. Bohm M, Ezekowitz MD, Connolly SJ et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015; 65: 2481–2493. Doi: 10.1016/j. jacc.2015.03.577

87. Doherty JU, Gluckman TJ, Hucker WJ et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69: 871–898. Doi: 10.1016/j.jacc.2016.11.024

88. Janssen MJ, Huijgens PC, Bouman AA et al. Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993;8:1228–1233. Doi: -

89. Glund S, Stangier J, van Ryn J et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumabmediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 2017; 56: 41–54. Doi: 10.1007/s40262-016-0417-0

90. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817. Doi: 10.1056/NEJMoa1007432.

91. Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–2434. Doi: 10.1056/NEJMoa1611594.

92. Reddy VY, Doshi SK, Kar S et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70: 2964–2975. Doi: 10.1016/j. jacc.2017.10.021.

93. Kefer J, Tzikas A, Freixa X et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol 2016; 207: 335–340. Doi: 10.1016/j.ijcard.2016.01.003.

94. Wyse DG, Waldo AL, DiMarco JP et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833. Doi: 10.1056/ NEJMoa021328

95. Testa L, Biondi-Zoccai GG, Dello Russo A et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005; 26: 2000–2006. Doi: 10.1093/eurheartj/ehi306

96. Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 2013; 36: 122–133. Doi: 10.1111/j.1540-8159.2012.03513.x.

97. Wyse DG. Rate control vs rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis 2005; 48: 125–138. Doi: 10.1016/j. pcad.2005.06.008

98. Verde E, Perez de Prado A, Lopez-Gomez JM et al. Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2016; 11: 2210–2217. Doi: 10.2215/CJN.04310416

99. Van Gelder IC, Groenveld HF, Crijns HJ et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363–1373. Doi: 10.1056/ NEJMoa1001337

100. Williams ES, Thompson VP, Chiswell KE et al. Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. Cardiol J 2013; 20: 439–446. Doi: 10.5603/CJ.2013.0104.

101. Potpara TS, Jokic V, Dagres N et al. Cardiac arrhythmias in patients with chronic kidney disease: implications of renal failure for antiarrhythmic drug therapy. Curr Med Chem 2016; 23: 2070–2083. Doi: –

102. Weir MA, Dixon SN, Fleet JL et al. beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987–996. Doi: 10.1681/ASN.2014040324

103. Hoffmann KJ, Regardh CG, Aurell M et al. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 1980; 5: 181–191. Doi: 10.2165/00003088-198005020-00005

104. https://www.drugbank.ca/drugs/DB00598 (13 February 2018).

105. Daheb K, Lipman ML, Hildgen P, Roy JJ. Artificial neural network modeling for drug dialyzability prediction. J Pharm Pharm Sci 2013; 16: 665–675. Doi: -

106. Frishman WSD. Cardiovascular Pharmacotherapies. Minneapolis, MN: Cardiotext Publisher; 2011

107. Dasgupta A, Montalvo J, Medendorp S et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007; 49: 656–663. Doi: 10.1053/j. ajkd.2007.02.272

108. Reinecke H, Nabauer M, Gerth A et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int 2015; 87: 200–209. Doi: 10.1038/ki.2014.195.

109. Schmidt M, Daccarett M, Rittger H et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 2011; 22: 1092–1098. Doi: 10.1111/j.1540-8167.2011.02069.x

110. https://www.drugbank.ca/drugs/DB01182 (13 February 2018).

111. Ullal AJ, Than CT, Fan J et al. Amiodarone and risk of death in contemporary patients with atrial fibrillation: findings from the Retrospective Evaluation and Assessment of Therapies in AF study. Am Heart J 2015; 170: 1033–1041. Doi: 10.1016/j.ahj.2015.07.023

112. Ullal AJ, Kaiser DW, Fan J et al. Safety and clinical outcomes of catheter ablation of atrial fibrillation in patients with chronic kidney disease. J Cardiovasc Electrophysiol 2017;28:39–48. Doi:10.1111/jce.13118

113. Li M, Liu T, Luo D, Li G. Systematic review and metaanalysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation. Cardiol J 2014;21:89–95 Doi:10.5603/CJ.a2013.0116

114. Yanagisawa S, Inden Y, Kato H et al. Impaired renal function is associated with recurrence after cryoballoon catheter ablation for paroxysmal atrial fibrillation: a potential effect of non-pulmonary vein foci. J Cardiol 2017;69:3–10 Doi: 10.1016/j.jjcc.2016.07.008

115. Takahashi Y, Takahashi A, Kuwahara T, et al. Renal function after catheter ablation of atrial fibrillation. Circulation 2011;124:2380–2387. Doi: 10.1161/CIRCULATION-AHA.111.047266

116. Marrouche NF, Brachmann J, Andresen D, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–427. Doi: 10.1056/ NEJMoa1707855

117. Marrouche NF, Brachmann J. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)—study design. Pacing Clin Electrophysiol 2009; 32:987–994. Doi: 10.1111/j.1540-8159.2009.02428.x

118. Kwon CH, Kim J, Kim MS, et al. Impact of impaired renal function on the incidence of atrial fibrillation following radiofrequency ablation of cavotricuspid isthmusdependent atrial flutter. Korean Circ J 2015;45:473–478. Doi:10.4070/kcj.2015.45.6.473

119. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:2050–2060. Doi: 10.1001/ jama.2013.280521

120. Lakkireddy D, Atkins D, Pillarisetti J, et al. Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study. J Am Coll Cardiol 2013;61:1177–1182. Doi: 10.1016/j.jacc.2012.11.060

121. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004;110:364–367. Doi: 10.1161/01.CIR.0000136587.68725.8E

122. Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a metaanalysis of observational studies. Europace 2014;16:1309–1314. Doi: 10.1093/europace/euu066

123. Meyring-Wosten A, Zhang H, Ye X et al. Intradialytic hypoxemia and clinical outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2016;11:616–625 Doi: 10.2215/CJN.08510815

124. Unruh ML, Sanders MH, Redline S, et al. Sleep apnea in patients on conventional thrice-weekly hemodialysis: comparison with matched controls from the Sleep Heart Health Study. J Am Soc Nephrol 2006;17:3503–3509. Doi: 10.1681/ASN.2006060659

125. Tuohy CV, Montez-Rath ME, Turakhia M, et al. Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. BMC Nephrol 2016;17:16. Doi: 10.1186/ s12882-016-0229-3

126. Charytan DM, Lewis EF, Desai AS, et al. Cause of death in patients with diabetic CKD enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2015;66:429–440. Doi: 10.1053/j.ajkd.2015.02.324

127. Deo R, Sotoodehnia N, Katz R, et al. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes 2010;3:159–164 Doi: 10.1161/CIRCOUTCOMES.109.875369

128. Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006;98:485–490. Doi: 10.1016/j. amjcard.2006.03.025

129. Pun PH, Smarz TR, Honeycutt EF, et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009;76:652–658 Doi: 10.1038/ki.2009.219

130. Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006;114:2766–2772. Doi: 10.1161/ CIRCULATIONAHA.106.642892

131. Suzuki T, Agarwal SK, Deo R, et al. Kidney function and sudden cardiac death in the community: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2016;180:46–53. Doi: 10.1016/j.ahj.2016.07.004

132. Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69: 2268–2273. Doi: 10.1038/sj.ki.5000446

133. Chan KE, Maddux FW, Tolkoff-Rubin N, et al. Early

134. outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol 2011;6:2642–2649. Doi: 10.2215/ CJN.03680411

135. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011;80: 572–586 Doi: 10.1038/ki.2011.223

136. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008;21:300–307. Doi: 10.1111/j.1525-139X.2008.00455.x

137. Robinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int 2014;85:158–165 Doi: 10.1038/ki.2013.252

138. Weinhandl E, Constantini E, Everson S, et al. Peer kidney care initiative 2014 report: dialysis care and outcomes in the United States. Am J Kidney Dis 2015;65:A6. Doi: 10.1053/j. ajkd.2015.03.021

139. U.S. Renal Data System, 2017 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2017. Doi: https:// Doi.org/10.1053/j.ajkd.2017.01.036

140. Wetmore JB, Gilbertson DT, Liu J, Collins AJ. Improving outcomes in patients receiving dialysis: the peer kidney care initiative. Clin J Am Soc Nephrol 2016;11: 1297–1304. Doi: 10.2215/ CJN.12981215

141. Chugh SS, Reinier K, Teodorescu C et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008;51:213–228 Doi: 10.1016/j.pcad.2008.06.003

142. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015;36:1990–1997. Doi: 10.1093/eurheartj/ehv186

143. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352: 2581–2588. Doi: 10.1056/NEJMoa043938

144. Pun PH, Herzog CA, Middleton JP. Improving ascertainment of sudden cardiac death in patients with end stage renal disease. Clin J Am Soc Nephrol 2012;7: 116–122. Doi: 10.2215/ CJN.02820311

145. Wan C, Herzog CA, Zareba W, Szymkiewicz SJ. Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. Ann Noninvasive Electrocardiol 2014;19:247–257. Doi: 10.1111/anec.12119

146. Wong MC, Kalman JM, Pedagogos E, et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm 2015;12:2047–2055. Doi: 10.1016/j.hrthm.2015.06.033

147. Pun PH, Lehrich RW, Honeycutt EF, et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011;79:218–227. Doi: 10.1038/ki.2010.315

148. Shastri S, Tangri N, Tighiouart H, et al. Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol 2012;7:123–130 Doi: 10.2215/ CJN.06320611

149. Friedman AN, Yu Z, Tabbey R, Denski et al. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int 2013;83:1130–1135 Doi: 10.1038/ki.2013.4

150. Kruzan RM, Herzog CA, Wu A et al. Association of NT-proBNP and cTnI with outpatient sudden cardiac death in hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. BMC Nephrol 2016; 17:18. https://Doi. org/10.1186/s12882-016-0230-x

151. Sandoval Y, Herzog CA, Love SA et al. Prognostic value of serial changes in high sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients. Clin Chem 2016; 62: 631–638. https://Doi.org/10.1373/ clinchem.2015.251835

152. Wang AY, Lam CW, Chan IH et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56: 210–216. https://Doi.org/10.1161/ HYPERTENSIONAHA.110.151167

153. Winkler K, Wanner C, Drechsler C et al. German Diabetes and Dialysis Study Investigators. Change in N-terminal-pro-B-typenatriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008;29: 2092–2099. https://Doi.org/10.1093/eurheartj/ehn278

154. Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia. J Am Coll Cardiol 2012;60:1993–2004. https://Doi. org/10.1016/j.jacc.2011.12.063

155. Roberts R, Jeffrey C, Carlisle G, Brierley E. Prospective investigation of the incidence of falls, dizziness and syncope in haemodialysis patients. Int Urol Nephrol 2007;39:275–279. https:// Doi.org/10.1007/s11255-006-9088-3

156. Charytan DM, Patrick AR, Liu J et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011;58:409–417. https://Doi.org/10.1053/j.ajkd.2011.03.026

157. Herzog CA, Li S, Weinhandl ED et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818–825. https://Doi. org/10.1111/j.1523-1755.2005.00462.x

158. Nakhoul GN, Schold JD, Arrigain S et al. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol 2015;10: 1119–1127. https://Doi.org/10.2215/CJN.11121114

159. Mallamaci F, Zoccali C, Tripepi G et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001;59: 1559–1566. https://Doi.org/10.1046/j.1523-1755.2001.0590041559.x

160. Sood MM, Pauly RP, Rigatto C, Komenda P. Left ventricular dysfunction in the haemodialysis population. NDT Plus 2008;1:199–205. https://Doi.org/10.1093/ndtplus/sfn074

161. Pun PH, Al-Khatib SM, Han JY et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis 2014;64:32–39. https://Doi.org/10.1053/j. ajkd.2013.12.009

162. El-Chami MF, Levy M, Kelli HM et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol 2015;26: 900–904. https://Doi.org/10.1111/jce.12705

163. Fotheringham J, Fogarty DG, El Nahas M et al. The mortality and hospitalization rates associated with the long interdialytic gap in thrice-weekly hemodialysis patients. Kidney Int 2015;88:569–575. https://Doi.org/10.1038/ki.2015.141

164. Brunelli SM, Du Mond C, Oestreicher N et al. Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval. Am J Kidney Dis 2017;70:21–29. https://Doi.org/10.1053/j.ajkd.2016.10.024

165. Rhee CM, Kalantar-Zadeh K. Implications of the long interdialytic gap: a problem of excess accumulation vs. excess removal? Kidney Int 2015;88:442–444. https://Doi.org/10.1038/ ki.2015.193

166. Ribeiro SC, Figueiredo AE, Barretti P, Pecoits-Filho R, de Moraes TP, Aguilera AI. all centers that contributed to BIIs. Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a Propensity-Matched Score Study. PLoS One 2015;10:e0127453. https://Doi.org/10.1371/journal. pone.0127453

167. Pitt B, Rossignol P. Potassium lowering agents: recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. Pharmacol Res 2017;118:2–4. https://Doi. org/10.1016/j.phrs.2016.07.032

168. Lepage L, Dufour AC, Doiron et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol 2015;10:2136–2142. https://Doi.org/10.2215/CJN.03640415

169. Berlyne GM, Janabi K, Shaw AB, Hocken AG. Treatment of hyperkalemia with a calcium-resin. Lancet 1966;1:169–172. https://Doi.org/10.1016/S0140-6736(66)92460-3

170. Weir MR, Bakris GL, Bushinsky DA et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372: 211–221 https://Doi.org/10.1056/ NEJMoa1410853

171. Weir MR, Bakris GL, Gross C et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int 2016;90:696–704. https://Doi.org/10.1016/j. kint.2016.04.019

172. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547–1559. https://Doi. org/10.1056/NEJMoa0801317

173. Parving HH, Brenner BM, McMurray JJ et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–2213. https://Doi. org/10.1056/NEJMoa1208799

174. Fried LF, Emanuele N, Zhang JH et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–1903. https:// Doi.org/10.1056/NEJMoa1303154

175. Quach K, Lvtvyn L, Baigent C et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2016;68:591–598. https://Doi.org/10.1053/j.ajkd.2016.04.011

176. Weir MR, Kline I, Xie J et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 2014;30:1759–1768. https://Doi.org/10.1185/03007995.2014 .919907

177. Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001;60: 350–357. https:// Doi.org/10.1046/j.1523-1755.2001.00806.x

178. Jadoul M, Thumma J, Fuller DS et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2012;7:765–774. https://Doi.org/10.2215/CJN.08850811

179. Karaboyas A, Zee J, Brunelli SM et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2017;69:266–277. https://Doi. org/10.1053/j.ajkd.2016.09.015

180. Heguilen RM, Sciurano C, Bellusci AD et al. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients. Nephrol Dial Transplant 2005;20:591–597. https://Doi.org/10.1093/ndt/gfh661

181. Saran R, Bragg-Gresham JL, Levin NW et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006;69:1222– 1228. https://Doi.org/10.1038/sj.ki.5000186

182. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009;4:1925–1931. https://Doi.org/10.2215/ CJN.04470709

183. Cabrera C, Brunelli SM, Rosenbaum D et al. A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients. BMC Nephrol 2015;16:113. https://Doi. org/10.1186/s12882-015-0110-9

184. Calkins H, Hindricks G, Cappato R et al. 2017 HRS/EHRA/ ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018;20:e1. https://Doi.org/10.1093/europace/eux275


Для цитирования:


Турахия М.П., Бланкештин П.Д., Карреро Х., Клазе К.М., Део Р., Герцог Ч.А., Каснер С.Е., Пассам Р.С., Пекуа-Фийо Р., Райнеке Х., Шрофф Г.Р., Зареба В., Чеунг М., Вилер Д.К., Ваннер К., Винкельмайер В.К. ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК И АРИТМИИ: ИТОГИ КОНФЕРЕНЦИИ KDIGO ПО СПОРНЫМ ВОПРОСАМ. Нефрология. 2019;23(2):18-40. https://doi.org/10.24884/1561-6274-2019-23-2-18-40

For citation:


Turakhia M.P., Blankestijn P.J., Carrero J., Clase C.M., Deo R., Herzog C.A., Kasner S.E., Passman R.S., Pecoits-Filho R., Reinecke H., Shrof G.R., Zareba W., Cheung M., Wheeler D.C., Wanner C., Winkelmayer W.C. CHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg). 2019;23(2):18-40. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-2-18-40

Просмотров: 176


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)